NCT06784349

ALN-APOC3 in Adult Participants With Dyslipidemia

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-APOC3 in Adult Participants With Dyslipidemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol), but who are otherwise healthy. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * How the study drug changes lipid levels in the blood

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	ALN-APOC3	Administered as per the protocol
DRUG	Matching Placebo	Administered as per the protocol

Timeline

• Start date: 2025-01-27
• Primary completion: 2026-02-25
• Completion: 2026-02-25
• First posted: 2025-01-20
• Last updated: 2026-03-16

Locations

1 site across 1 country: Moldova

Regulatory

• FDA-regulated drug study